


R&D Pipeline



antibody



protein



small molecule

© New Molecular Entity

Updated since Dec. 31, 2021



Updated since Dec. 31, 2021

Nephrology

As of March 31, 2022

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KHK7580 Evocalcet Oral	Calcimimetic	Secondary Hyperparathyroidism	CN Asia						[Mitsubishi Tanabe Pharma] product name in Japan: Orkedia
© RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	Alport Syndrome	JP						[Reata]
		Diabetic Kidney Disease	JP						
		Autosomal Dominant Polycystic Kidney Disease	JP						
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Preeclampsia	JP						[In-House] product name in Japan: Acoalan
KHK7791 Tenapanor Hydrochloride Oral	NHE3 Inhibitor	Hyperphosphatemia in Patients on Dialysis	JP						[Ardelyx]

Oncology

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome	CA CN KR KW						[In-House] POTELLIGENT® product name in Japan, U.S. and Europe: Poteligeo
KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony- Stimulating Factor	Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Allogeneic Blood Stem Cell Transplantation	JP						[Amgen K-A] product name in Japan: G-Lasta
		Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Blood Stem Cell Transplantation	JP						
		Automated Injection Device for Decreasing the Incidence of Febrile Neutropenia in Patients Receiving Cancer Chemotherapy	JP						
© KHK2455 Oral	IDO1 Inhibitor	Solid Tumor	NA						[In-House] Combination with KW-0761
		Urothelial carcinoma	NA						[In-House] Combination with avelumab
			Europe						
© ME-401 Zandelisib Oral	PI3Kδ Inhibitor	Follicular Lymphoma and Marginal Zone Lymphoma	JP NA Europe Asia Oceania others						[MEI Pharma] Combination with rituximab Second line +
		Follicular Lymphoma	NA						[MEI Pharma] Third line +
		Marginal Zone Lymphoma	Europe Asia Oceania						
		Indolent B-cell Non-Hodgkin's Lymphoma	JP						[MEI Pharma] Third line +
		B-cell malignancies	NA						[MEI Pharma] Monotherapy, combination with rituximab and combination with zanubrutinib

R&D Pipeline



antibody



protein



small molecule

© New Molecular Entity



Updated since Dec. 31, 2021



Updated since Dec. 31, 2021

Immunology/Allergy

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Ankylosing Spondylitis	TW	→					[Amgen K-A] product name in Japan: Lumicef
		Ankylosing Spondylitis	MY TL	→					
		Non-radiographic Axial Spondyloarthritis	TL	→					
		Systemic Sclerosis	JP	→					
		Palmoplantar Pustulosis	JP	→					
©KHK4083/AMG 451 Rocatinimab Injection	Anti-OX40 Fully Human Antibody	Atopic Dermatitis	JP NA Europe	→					[In-House] POTELLIGENT [®] Human Antibody-Producing Technology Collaboration agreement with Amgen for the development of KHK4083/AMG 451 in all the countries except for Japan.

Central Nervous System

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
©KW-6356 Oral	Adenosine A _{2A} Receptor Antagonist/Inverse Agonist	Parkinson's Disease	JP	→					[In-House]
©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	JP Europe	→					[Immunas Pharma]

Since the development of KW-6002 for Parkinson's Disease was discontinued in Europe, the relevant information was deleted from this table.

Other

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	TL	→					[In-House] Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU product name in Japan, U.S. and Europe: Crysvida
		Tumor Induced Osteomalacia (TIO)	MY Europe	→					
AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP) Who Do Not Respond Well to Other Treatments, Such as Corticosteroids and Immunoglobulin	CN	→					[Amgen K-A] product name in Japan: Romiplate
		Treatment of Adult Aplastic Anemia Refractory to Conventional Therapies	MY SG	→					
		Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP) Who Are Refractory to Other Treatments and Treatment of Adult Patients with Aplastic Anemia Who Are Refractory to Conventional Therapy	TL	→					
		Aplastic Anemia Who Were Previously Untreated with Immunosuppressive Therapy	JP Asia	→					
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Europe	→					[In-House] product name in Japan: Acoalan
KHK4951 Ophthalmic		Wet Age-Related Macular Degeneration	JP	→					[In-House]